2seventy bio, Inc. (TSVT)
TSVT Chart as of 2025-03-11
Stock Information
| CEO: | – |
| CFO: | – |
| Employees: | 274 |
| Address: | 60 Binney Street, Cambridge, MA, United States |
| Country: | United States |
| Website: | https://www.2seventybio.com |
| Listing Date: | – |
| Founded: | – |
| Founder: | – |
| Current Price: | 4.95 USD |
| Today Change: | 76.79% |
| Outstanding Shares: | 51,588,400 |
| Volume: | 583,456 |
| Avg Volume: | 336,275 |
| Expert Target Price: | 7.5000 (Institutions: 0) |
| EPS: | – |
| PER: | – |
| Dividend Date: | – |
| Last Split Date: | – |
| Last Split Factor: | – |
Key Executives
| Name | Title | Pay | Year |
|---|---|---|---|
| Mr. William D. Baird III, M.B.A. | CEO, President & Director | 708k | — |
| Ms. Victoria Eatwell | Chief Financial Officer | — | — |
| Ms. Jessica Snow | Chief Operating Officer | — | — |
Financials
Income Statement
| Metric | Amount |
|---|---|
| Total Revenue | 100,387,000 |
| Cost Of Revenue | 16,918,000 |
| Gross Profit | 83,469,000 |
| Operating Income | -216,703,000 |
| Net Income | -217,570,000 |
Balance Sheet
| Metric | Amount |
|---|---|
| Total Assets | 565,426,000 |
| Total Liabilities | – |
| Total Stockholder Equity | – |
Cash Flow
| Metric | Amount |
|---|---|
| Total Cash From Operating Activities | – |
| Capital Expenditures | – |
SEC Filings (Gemini Summaries)
| AccNo | Date | Summary |
|---|---|---|
| 0001860782-25-000008 | 2025-02-06 | 2seventy bio (TSVT) 8-K filing, Feb 6, 2025: Abecma U.S. revenue was ~$59M in Q4 2024 and ~$242M for 2024. Profits/losses are shared equally with BMS. Based on BMS data and is unaudited. Includes forward-looking statements. |
| 0001562180-25-000457 | 2025-01-22 | SEC Form 4/A filing by Jessica Snow, an officer at 2seventy bio, Inc. (TSVT), reporting changes in beneficial ownership of common stock on 01/06/2025. The filing amends a previous one from 01/07/2025. 1,838 shares were disposed of at $2.7944, leaving Snow with 150,527 shares. The transaction was pursuant to a Rule 10b5-1 plan. |
| 0001860782-25-000004 | 2025-01-10 | 2seventy bio (TSVT) filed an 8-K report on Jan 10, 2025, regarding Jessica Snow’s appointment as Chief Operating Officer, effective Jan 6, 2025. Compensation details are forthcoming in an amendment. |
| 0001562180-25-000280 | 2025-01-08 | SEC Form 4 filing by Jessica Snow, an officer at 2seventy bio, Inc. (TSVT). Reports a transaction on 01/06/2025 involving common stock. Snow acquired 106,150 shares and now owns 253,329 shares. |
| 0001562180-25-000279 | 2025-01-08 | SEC Form 4 filing by Victoria Eatwell, CFO of 2seventy bio, Inc. (TSVT), reporting an acquisition of 108,000 shares of common stock on 01/06/2025, resulting in beneficial ownership of 446,979 shares. |
News Summary
– 2seventy bio (TSVT) Projected to Post Earnings on Tuesday
2025-03-02 06:20:45 | ETF Daily News
2seventy bio (NASDAQ:TSVT – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $12.84 million for the quart…
Link
– 2seventy bio (NASDAQ:TSVT) Earns Sell (D-) Rating from Weiss Ratings
2025-03-09 06:46:47 | ETF Daily News
2seventy bio (NASDAQ:TSVT – Get Free Report)‘s stock had its “sell (d-)” rating reissued by equities researchers at Weiss Ratings. Shares of TSVT stock opened at $2.66…
Link
– 2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Average PT from Brokerages
2025-02-16 06:35:25 | ETF Daily News
2seventy bio, Inc. (NASDAQ:TSVT) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the stock. One analyst has rated the stock with a sell rati…
Link
– Rhumbline Advisers Has $249,000 Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT)
2025-03-10 07:21:07 | ETF Daily News
Rhumbline Advisers raised its holdings in 2seventy bio, Inc. (NASDAQ:TSVT – Free Report) by 9.5% during the 4th quarter. The firm owned 84,670 shares of the company’s stock after buying an a…
Link
Analysis of Today’s Move
Here’s an analysis of the potential reasons behind a recent rally in 2seventy bio (TSVT) stock, based on the provided information:
The upcoming earnings report, scheduled for Tuesday, March 4th, likely contributed to speculative buying. Analysts projected a loss of ($0.20) per share and revenue of $12.84 million. Investor anticipation, even for potentially negative news, can drive short-term price increases. This is especially true for volatile biotech stocks.
Recent SEC filings reveal increased ownership by company officers. Both Victoria Eatwell (CFO) and Jessica Snow acquired significant shares on January 6, 2025. These acquisitions signaled confidence in the company’s future prospects. Such insider buying is often viewed positively by the market.
Rhumbline Advisers increased their holdings in TSVT during the fourth quarter. They increased their position by 9.5%, owning 84,670 shares. This institutional investment also suggests positive sentiment. Increased institutional ownership can drive demand and stock price appreciation.
The average price target of $7.20 from brokerages may have played a role. Despite a “sell (D-)” rating from Weiss Ratings, the overall consensus was “Moderate Buy”. This discrepancy creates a mixed, but potentially optimistic, outlook. Investors may focus on the higher price target possibilities.
While a “sell” rating exists, the other factors likely outweighed the negative sentiment. The insider buying, increased institutional ownership, and upcoming earnings drove optimism. These events combined create a scenario for a temporary stock rally. Long-term sustainability depends on future performance and earnings results.
This stock has shown a change of 76.79% today.
Please consider that all investment decisions carry risk;
none of the content here should be construed as financial advice.
Always do your own research or consult a professional before making investment decisions.
The information provided in this article is for informational purposes only
and does not constitute legal, tax, or investment advice.
Investing involves risk, including the potential loss of principal.
Leave a Reply